Articles On Regeneus (ASX:RGS)

Australian regenerative medicine company, Regeneus (ASX: RGS), has announced that Kyocera has signed a licence agreement to develop and commercialise Progenza for knee osteoarthritis in Japan.

A quick wrap of the ASX’s key winners and losers on Wednesday, August 5. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 681 stocks rose, 607 declined and...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week With quart...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Clinical t...

Our summary of Regeneus Ltd's recent announcement What's happened? Regeneus Ltd (ASX: RGS, “Regeneus”) tday announced it has received notification that Kyocera Corporation (TYO:6971) has completed its due diligence process on its lead stem...

Sydney-based clinical-stage regenerative medicine company Regeneus (ASX:RGS) has received a non-refundable milestone payment of approximately $1.6 million (100 million Japanese Yen) from Kyocera Corporation.

Clinical-stage regenerative medicine company Regeneus Ltd (ASX:RGS) announced on Monday morning that the US Patent and Trademark Office (USPTO) had issued a notice of allowance for issuance of a new key patent for the company’s lead stem ce...

Sydney-based clinical-stage regenerative medicine company, Regeneus Ltd (ASX:RGS) today received a non-refundable milestone payment of ¥100,000,000 (approx. A$1.6M) from Kyocera Corporation (TYO:6971). The payment was made in regards to a n...

As with the early medical cannabis plays, a cluster of ASX-listed stocks has wasted little time attaching itself to the ‘c’ word. We’re talking of course about the coronavirus COVID-19 but sadly not another ‘c’ word: cure. Or not yet. Accor...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Clinical stage regenerative medicine company Regeneus Ltd (ASX:RGS) has signed a non-binding memorandum of understanding (MOU) with Kyocera Corporation (Kyocera, TYO:6971), a diversified Japanese-based manufacturer with a strong position in...

Biotech company Regeneus (ASX:RGS) is a regenerative medicine company, and the therapy is a novel stem cell therapy.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Asia is rising as a healthcare spender, matching incomes and the long-feared elderly population boom. The region is a major part of a surge in health spending that is expected over the next few years, as rising lifestyle illnesses and ages...

Drug development is an extensive process and includes drug discovery & development, pre-clinical and clinical research and FDA approvals, including Post-Market Drug Safety Monitoring. The first and the most essential step of drug devel...

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, has placed the full shortfall of 9,437,872 shares under its recent Non-Renounceable Rights Issue. The placement to a Japan-based institutional investor with extensive e...

Drug Development Process The drug development process starts from drug discovery and ends at the launch of the new pharmaceutical product in the market. The process includes drug discovery and development, preclinical trials, clinical trial...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

Regeneus Limited (ASX: RGS) received a R&D tax incentive of $1.5 million from Australian Tax Office for FY19. This tax incentive has enabled the repayment of $1.3 million Paddington Street Loan which will allow the release of Paddingto...

Investing in Small-Cap Stocks Biotech is a dynamic and profitable sector for investors. Capital venture in biotech stocks provides great enthusiasm and diversification support to market fans. In general, before investing money in stocks, in...

On 15 August 2019, the S&P/ASX 200 Health Care Index is down 2.48% to 34,883, while the benchmark index S&P/ASX 200 was down by 2.65% and trading at 6,425.5 (as at AEST: 2:08 PM). In this article, we will discuss four stocks that ar...

Cirrus Networks Holdings Limited updated the exchange on its recent contract wins and provided the market update on the results for FY19. Regeneus Limited released an announcement regarding the pro-rata entitlement offer along with an updat...

Australian clinical-stage regenerative medicine company, Regeneus Ltd (ASX: RGS) recently announced positive results from its preclinical trial of Progenza in the treatment of allodynia, a condition in which pain occurs from non-painful sti...

Special Report: Stem cells still have somewhat of a bad rep, as news headlines either repeat the embryo origin story or recount shills promising them as a cure-all for everything from ADHD to Alzheimer’s. But beneath those headlines is a fl...